257 related articles for article (PubMed ID: 38555429)
21. Retrospective study of transcriptomic profiling identifies Thai triple-negative breast cancer patients who may benefit from immune checkpoint and PARP inhibitors.
Suntiparpluacha M; Chanthercrob J; Sa-Nguanraksa D; Sitthikornpaiboon J; Chaiboonchoe A; Kueanjinda P; Jinawath N; Sampattavanich S
PeerJ; 2023; 11():e15350. PubMed ID: 37334114
[TBL] [Abstract][Full Text] [Related]
22. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial.
Jiang YZ; Liu Y; Xiao Y; Hu X; Jiang L; Zuo WJ; Ma D; Ding J; Zhu X; Zou J; Verschraegen C; Stover DG; Kaklamani V; Wang ZH; Shao ZM
Cell Res; 2021 Feb; 31(2):178-186. PubMed ID: 32719455
[TBL] [Abstract][Full Text] [Related]
23. Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease.
Mehlich D; Marusiak AA
Cancer Lett; 2022 Oct; 547():215775. PubMed ID: 35667515
[TBL] [Abstract][Full Text] [Related]
24. Triple Negative Breast Cancer: A Tale of Two Decades.
Ali AM; Ansari JAK; El-Aziz NMA; Abozeed WN; Warith AMA; Alsaleh K; Nabholtz JM
Anticancer Agents Med Chem; 2017; 17(4):491-499. PubMed ID: 27456662
[TBL] [Abstract][Full Text] [Related]
25. Triple-negative breast cancer and basal-like subtype : Pathology and targeted therapy.
Bando Y; Kobayashi T; Miyakami Y; Sumida S; Kakimoto T; Saijo Y; Uehara H
J Med Invest; 2021; 68(3.4):213-219. PubMed ID: 34759133
[TBL] [Abstract][Full Text] [Related]
26. The Landscape of Targeted Therapies in TNBC.
Vagia E; Mahalingam D; Cristofanilli M
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32276534
[TBL] [Abstract][Full Text] [Related]
27. A ten long noncoding RNA-based prognostic risk model construction and mechanism study in the basal-like immune-suppressed subtype of triple-negative breast cancer.
Huang X; Huang J; Huang Q; Zhou S
Transl Cancer Res; 2023 Dec; 12(12):3653-3671. PubMed ID: 38193005
[TBL] [Abstract][Full Text] [Related]
28. Feasibility of Classification of Triple Negative Breast Cancer by Immunohistochemical Surrogate Markers.
Kim S; Moon BI; Lim W; Park S; Cho MS; Sung SH
Clin Breast Cancer; 2018 Oct; 18(5):e1123-e1132. PubMed ID: 29754847
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.
Burstein MD; Tsimelzon A; Poage GM; Covington KR; Contreras A; Fuqua SA; Savage MI; Osborne CK; Hilsenbeck SG; Chang JC; Mills GB; Lau CC; Brown PH
Clin Cancer Res; 2015 Apr; 21(7):1688-98. PubMed ID: 25208879
[TBL] [Abstract][Full Text] [Related]
30. Enhancing therapeutic efficacy in luminal androgen receptor triple-negative breast cancer: exploring chidamide and enzalutamide as a promising combination strategy.
Zhao YX; Wang H; Zhang SW; Zhang WX; Jiang YZ; Shao ZM
Cancer Cell Int; 2024 Apr; 24(1):131. PubMed ID: 38594722
[TBL] [Abstract][Full Text] [Related]
31. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
[TBL] [Abstract][Full Text] [Related]
32. Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo.
Barton VN; D'Amato NC; Gordon MA; Lind HT; Spoelstra NS; Babbs BL; Heinz RE; Elias A; Jedlicka P; Jacobsen BM; Richer JK
Mol Cancer Ther; 2015 Mar; 14(3):769-78. PubMed ID: 25713333
[TBL] [Abstract][Full Text] [Related]
33. Estrogen receptor beta suppresses the androgen receptor oncogenic effects in triple-negative breast cancer.
Xu F; Xu K; Fan L; Li X; Liu Y; Yang F; Zhu C; Guan X
Chin Med J (Engl); 2024 Feb; 137(3):338-349. PubMed ID: 38105538
[TBL] [Abstract][Full Text] [Related]
34. Triple-negative breast cancer: advancements in characterization and treatment approach.
Hurvitz S; Mead M
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
[TBL] [Abstract][Full Text] [Related]
35. A comparison of the molecular subtypes of triple-negative breast cancer among non-Asian and Taiwanese women.
Tseng LM; Chiu JH; Liu CY; Tsai YF; Wang YL; Yang CW; Shyr YM
Breast Cancer Res Treat; 2017 Jun; 163(2):241-254. PubMed ID: 28299476
[TBL] [Abstract][Full Text] [Related]
36. Characteristics of triple-negative breast cancer.
de Ruijter TC; Veeck J; de Hoon JP; van Engeland M; Tjan-Heijnen VC
J Cancer Res Clin Oncol; 2011 Feb; 137(2):183-92. PubMed ID: 21069385
[TBL] [Abstract][Full Text] [Related]
37. Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies.
Gupta GK; Collier AL; Lee D; Hoefer RA; Zheleva V; Siewertsz van Reesema LL; Tang-Tan AM; Guye ML; Chang DZ; Winston JS; Samli B; Jansen RJ; Petricoin EF; Goetz MP; Bear HD; Tang AH
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32846967
[TBL] [Abstract][Full Text] [Related]
38. Triple-negative breast cancer and poly(ADP-ribose) polymerase inhibitors.
Park Y; Moriyama A; Kitahara T; Yoshida Y; Urita T; Kato R
Anticancer Agents Med Chem; 2012 Jul; 12(6):672-7. PubMed ID: 22263793
[TBL] [Abstract][Full Text] [Related]
39. More Than Meets the Eye: A Case of Breast Cancer Switching from Being Luminal-Androgen-Receptor-Positive to Being Hormone-Receptor-Positive.
Martorana F; Di Grazia G; Rosano GN; Vecchio GM; Conti C; Nucera S; Magro G; Vigneri P
Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893593
[TBL] [Abstract][Full Text] [Related]
40. Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response.
Thompson KJ; Leon-Ferre RA; Sinnwell JP; Zahrieh DM; Suman VJ; Metzger FO; Asad S; Stover DG; Carey L; Sikov WM; Ingle JN; Liu MC; Carter JM; Klee EW; Weinshilboum RM; Boughey JC; Wang L; Couch FJ; Goetz MP; Kalari KR
NAR Cancer; 2022 Jun; 4(2):zcac018. PubMed ID: 35734391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]